Advanced lung cancer patients with EGFR mutations typically show hypersensitivity to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib (Lynch et al., 2004; Paez et al., 2004; Rosell et al., 2009). This evidence concerns the gene EGFR and lung cancer.